


R L P G C M
 C P W T D H19^{Δ13}

Clive J. Petry,¹ Mark L. Evans,^{2,3} Dianne L. Wingate,¹ Ken K. Ong,^{1,4} Wolf Reik,^{5,6}
 Miguel Constância,^{3,5,6,7} and David B. Dunger^{1,3}

H19



RESULTS


IGF2 levels in H19^{Δ13} mice were significantly lower than in control mice (1, 2 ± 2 , 1 ± 10 , $P = 0.01$).

IGF2 levels in H19^{Δ13} mice were significantly lower than in control mice (1, 0.2 ± 21 , 1 ± 1 , $P = 0.00$).

CONCLUSIONS

IGF2 levels in H19^{Δ13} mice were significantly lower than in control mice (1, 0.2 ± 21 , 1 ± 1 , $P = 0.00$).

Diabetes 59:282–286, 2010²



RESEARCH DESIGN AND METHODS

Animals.

IGF2 levels in H19^{Δ13} mice were significantly lower than in control mice (1, 0.2 ± 21 , 1 ± 1 , $P = 0.00$).

IGF2 levels in H19^{Δ13} mice were significantly lower than in control mice (1, 0.2 ± 21 , 1 ± 1 , $P = 0.00$).

IGF2 levels in H19^{Δ13} mice were significantly lower than in control mice (1, 0.2 ± 21 , 1 ± 1 , $P = 0.00$).


IGF2 levels in H19^{Δ13} mice were significantly lower than in control mice (1, 0.2 ± 21 , 1 ± 1 , $P = 0.00$).

2 (1, u) 2 (10, u) 1% (/)
H19
10

/T1 11T 1. (0 . 0010 . . (T₁ (0)T1/T1 01T 1.(1 /T1 01T 0T /T1 01T (-T₁/T1 01T 0T /T1 01T (00 . .1 (0 (2-2 1
H19



1, 02 ±



(20),

(21),

$H_{19}^{\Delta B}$

I_2

H_{19}

I_2

(2),

$H_{19}^{\Delta B}$

(2),

(1),

H_{19}

(2),

(10,11)

ACKNOWLEDGMENTS

(0 00)

REFERENCES

1. 200 (2) 0 1 0
2. 200 1
- 200 1 2 1
- 1 0
- 200 1 1 21 2
- 1 1 1 1
- 200
- 200 22
10. 200 22
11. 1

2002 2 1
20
12. T, u
200 12 2 0
1. 200 102 1 21 1 22
1. 200 2 1 1
1. 200 2 2 1 2 0
1. 200 1 1 1 1
1. 200 1
1. 200 2
1. 200 1 0 1 1 1 2
20.

21. 1 2 0
200
22. 1 1 1 1
2. T, u
1 2
2. 200 2 1
1- T, u